Rising Leaders 2025: Aneesh Karatt-Vellatt On Maxion Therapeutics’ Antibody Revolution

Earlier this year our Co-founder and CSO, @Aneesh Karatt-Vellatt, was named a 2025 Rising Leader by @Citeline’s In Vivo. 

Aneesh sat down with @Jo Shorthouse to talk discuss how Maxion Therapeutics is using its KnotBody® platform to redefine how membrane proteins such as ion channels and G protein-coupled receptors (GPCRs) are targeted. Ion channel and GPCR disfunction are implicated in a wide range of debilitating diseases and current treatments based on small molecule drugs suffer from poor efficacy and side effects.

Many congratulations to Aneesh on being selected to participate and to our entire team for pushing the boundaries of what's possible in antibody therapeutics! 🧬

Read the full article here: Rising Leaders 2025: Aneesh Karatt-Vellatt On Maxion Therapeutics’ Antibody Revolution

‍